الفهرس 
Alopecia AreataOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Shawky Mahmoud modulated by the up-regulation of receptor levels by inflammatory mediators such as TNF-α or by angiogenic factors such as VEGF and bFGF.
CXCL12 acts as an amplifying factor by enhancing VEGF production and VEGF and bFGF in turn enhance CXCL12 expression.
This study aimed at measuring the serum levels of CXCL12 in the patients suffering from AA in comparison to healthy controls in an attempt to evaluate its role in the pathogenesis of the disease.
This case control study was carried out on 25 patients with AA and 25 age and gender matched healthy subjects as a control group. Patients were selected from Dermatology Outpatient clinic, Menoufia University hospitals and Menouf General Hospital, from February 2018 to August 2018. A written consent was taken from every participant and the study was approved by the Ethical Committee of Medical research of Menoufia Faculty of Medicine.
All studied subjects were submitted to complete history taking, clinical and dermatological examination. Blood samples were taken from all subjects to assess serum CXCL12 level. The obtained data was tabulated and statistically analyzed.
The results of the present study can be summarized as follows:
Alopecia Areata patients were 15 males (60%) and 10 females (40%), with age ranging from 12 to 50 years with mean 29.24 ±10.50 years. The mean duration of their disease was 8.13±5.61m. The controls group included 25 age and sex matched apparently healthy individuals. They were 10 (40%) males and 15 females (60%), with age ranging from 16 to 45 years with mean ± SD 27.28 ± 7.38 years. There is no significant difference between the two groups regarding age and gender.
There is significant statistical difference between studied groups regarding CXCL 12 level. Also the quantitative estimation of level of CXCL12 in the two groups was found to be significantly decreased in patients with mean ± SD 15.55 ± 6.35U/ml and 46.94 ± 41.42 for controls.
There is negative significant correlation between CXCL12 and duration of disease. Wherease non-significant negative correlation existed with age and size of lesion.
There is no significant statistical difference in CXCL 12 level regarding gender, onset, course of AA.
Regarding to distribution of the studied patients according to site, most common site of lesions is scalp.
There is dependant relationship between AA and CXCL12 serum level. At Cut off value of CXCL12 ≤23.20 (ng/ml), the sensitivity was 92%, Specificity 52% , PPV 65.7 % , and NPV 86.7 % for differentiation of patients vs controls.
.